Revvity, Inc. · NYSE:RVTY
Revvity — Perkinelmer — Merger or Acquisition (October 2005)
9 slides from Revvity's merger presentation, Oct 7, 2005
Slide 1: Focusing on Health Sciences & Photonics
Focusing on Health Sciences & Photonics October 6, 2005
Slide 2: Factors Affecting Future Performance
Factors Affecting Future Performance This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth an
Slide 3: Today's discussion
Today’s discussion … Signed Contract to Sell Aerospace Business to Eaton Corporation Intention to Sell Semicon and Fluid Testing Businesses Potential Use of Proceeds Financial Implication PKI Post-Fluid Sciences Sale … accelerating shift to Health Sciences & Photonics
Slide 4: Sale of Aerospace business
Sale of Aerospace business … Buyer Eaton Corporation Proceeds ~ $330 million Expected Closing 4th Quarter 2005 2005E EBITDA ~ $34 million After-tax Proceeds ~ $240 million Book Gain > $1.00 per share Note: All figures presented are estimates … realizing good value
Slide 5: Semicon and Fluid Testing
Semicon and Fluid Testing … Range of Proceeds $60 - $75 million Expected Closing 4th Quarter 2005 2005E EBITDA ~ $10 million After-tax Proceeds ~ $55 million Book Gain $.20 - $.25 per share Note: All figures presented are estimates … in late stage negotiations
Slide 6: Potential use of proceeds
Potential use of proceeds … Repay indebtedness – outstanding balance $270M Licensing and acquisition Genetic Screening Service Medical Imaging Molecular Medicine Share buyback, ~10 million shares authorization … reinvest in growth platforms
Slide 7: Potential 2006 financial impact
Potential 2006 financial impact … Fluid Sciences 2006 Est. Operating Income ($40M - $43M) Interest Savings from Sub-note $24M Pre-Tax Impact ($16M - $19M) After-Tax Impact ($10M - $12M) EPS Impact (.07 - .09) ThomsonTM First Call EPS $1.28 per share Estimated 2006 EPS Dilution 5%-7% Note: All figure
Slide 8: PKI forecast post sale of Fluid Sciences
PKI forecast post sale of Fluid Sciences … 2005E 1.5B+ Revenue Health Sciences Genetic Screening Medical Imaging Service Biopharma Environmental 82% 18% Photonics Sensors Specialty Lighting * Excludes intangibles amortization and Q2 ’05 gains, restructuring and tax benefit 2005 Forecast Proforma w/o
Slide 9: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Use of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures of earnings per share operating profit and operating margin in each case exclude amortization of acquisition-related intangible assets and restructuring changes. This presenta